Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rush is speaking of his Lung cancer treatment right now
Maybe someone can inform him about Leronlimab he's speaking of horrible side effects of his current treatment
Leronlimab has stopped circulating tumor cells in Dr P's mother in law for Stage 3 breast cancer, maybe would be effective on his lung cancer
I would say 1.75 to 1,85 tomorrow unless we get major news coverage then 2.25 to 2.75. IMO
looks like their address is legit...in a bank building from what I see on G-maps
another 5500 @ 1.25
picked up another 5k @ 1.27
agreed .... may be last chance to load cheapies
not sure if this has been posted yet
BRONX, N.Y., May 21, 2020 /PRNewswire/ -- Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the "cytokine storm" that inflames and fatally damages the lungs and other organs of many COVID-19 patients.
Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic, and realized its potential for treating his transplant patients who had COVID-19. He then obtained "compassionate use" permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.
"By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients," said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the "cytokine storm." Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs.
On May 5th, a study describing promising results for those 10 severely ill patients was made public on the website, MedRxiv, a resource especially useful during the COVID-19 pandemic to make research quickly available to the scientific community. Co-authored by Dr. Seethamraju, the study reported that five of the 10 patients treated with leronlimab survived; the study also described the drug as "a novel approach" to resolving unchecked inflammation.
Based on the positive results with those patients, the FDA approved Dr. Seethamraju's application for a phase 2 trial of leronlimab. That trial began enrolling both inpatients and outpatients with mild-to-moderate COVID-19 on April 2. A total of 75 will participate.
"Such patients all too often seem to be recovering, but then crash and burn when their lungs are overwhelmed by an inflammatory reaction that makes breathing impossible, "says Dr. Seethamraju. "The FDA is concerned that there is no treatment for those people."
Patients in the multicenter trial receive two injections, one week apart, of either leronlimab or a placebo and are assessed periodically over six weeks for fever, muscle pain, difficulty breathing and cough. Dr. Seethamraju is a co-principal investigator of the Montefiore trial site, along with Scott A. Scheinin, M.D., surgical director of advanced pulmonary failure and lung transplantation, division chief of thoracic surgery and surgical oncology, and director of the Bloodless Heart Surgical Program at Montefiore.
On April 16th, Montefiore enrolled the first patient in a second FDA-approved leronlimab clinical trial: a randomized, double blind trial to assess the optimal dose, safety and effectiveness of leronlimab in treating severely ill COVID-19 patients. The 390 patients taking part in this multicenter trial will receive two weekly doses of either leronlimab or a placebo; there will be twice as many patients receiving leronlimab as those receiving the placebo. The trial will evaluate the patients' survival at 14- and 28-days following treatment.
The two leronlimab clinical trials are being conducted under the direction of the departments of cardiothoracic surgery and medicine at Montefiore and Einstein. Leronlimab is a monoclonal antibody drug developed by CytoDyn Inc., a biotechnology company based in Vancouver, WA.
easy stock to hold....Q2 already a blowout, no need to sell....I can wait till Q2 numbers for a jump to 4-5$ imo
a little profit taking.... healthy....I prefer a slow and steady climb, unless of course we get some well deserved national attention.
Sooner or later the national media spotlight will focus on the clean up and the demand for sterile environments..... workplaces, restraunts, etc.
yes...no reason to sell when Q2 already blowing away Q1
Great part of being in this stock is that you don't have to worry about Q2 earnings.....since on CC they said already above Q1 numbers as of this week!!!!
No reason to sell with that info....still a month and a half left in Q2
If service masters or any of the other big cleaning/recovery companies thinking of buying out TOMZ they better move fast
I think he said Q2 already over Q1 numbers. !!!!!!!!!!!!
GUAM HOTEL DISENFECTION FOR NAVY !!!!!
Yes... mind-blowing.... if we get FDA approval for food we are all going to retire on this !!!!!!
Havard study on Sterimist !!!!! for decontaming masks !!!
6000% hospital growth
463% growth over Q1. 2019
etc
6000% hospital growth
463% growth over Q1. 2019
etc
FAA and car dealers.... just a few he's speaking of
prisons , restraints , retail, day care etc... etc
Love the dig at California to start call. !!!!
Don't forget. 4:30 pm EST conference call
register at their web site. www.tomimist.com
First Quarter 2020 Financial Results Conference Call
Monday, May 18, 2020
4:30 PM Eastern Time
report shows 2 cents per share earnings....unheard of for OTC.... would be funny if gave dividend
about time we get some respect regarding price
....looks like zero debt...seems like dilution done (read Q1 info)
we will continue to increase in PPS as more people learn about STERIMIST IMO
The problem is meeting demand..and that's not a bad problem
ignore big board. he does same thing over at the CYDY board. short all small Pharma
should make another run towards 9
preclinical results, 1-2 years away
I can see Q2 being even bigger than Q1 numbers...Demand can only get bigger as countries begin to open up...I could foresee window decals on businesses that say "This establishment disinfected by STERIMIST"
I think this is why we were stuck in the mid 50 cent range so long, but looks like note has been converted to stock....does this mean no more debt ??
In March 2020, convertible notes with a principal balance of $4,500,000 were converted into 8,333,332 shares of our common stock at a conversion price of $0.54 per share and the remaining outstanding balance of $500,000 was repaid in the form of cash. With respect to the 999,998 warrants issued as part of the convertible note transaction, 799,999 warrants expired in March 2020. In March 2020, 83,333, warrants were exercised, and 116,666 warrants expired in May 2020.
them being quite is just a chance for us to load up b-4 the bust out imo
can't wait to see what happens when word gets out...slow and steady increase for now
HOSPITAL REVENUES UP 6000%. !!!!!!!!!!!!!
Our Hospital-Healthcare revenues grew by approximately 6,000% in the first quarter of 2020 when compared to the same prior year period. The growth was primarily attributable to the significant demand for our product as a result of the SARS CoV-2 coronavirus global pandemic. We anticipate continued growth in this sector as hospital-healthcare facilities review and adopt new processes and technologies to address current and future outbreaks. We cannot predict the frequency or volume of orders as the world's response to decontamination and disinfecting is evolving. However, we anticipate continued growth moving into 2020.
from the report
Total revenue for the three months ended March 31, 2020 and 2019, was approximately $7,053,000 and $1,253,000, respectively, representing an increase of $5,800,000, or 463% compared to the same prior year period. The increase in revenue was attributable to increased global demand for disinfection and infectious disease control products in response to the SARS CoV-2 coronavirus global pandemic. In the first quarter we saw significant demand for our product with our Hospital-Healthcare and TSN sales as a result of the SARS CoV-2 coronavirus global pandemic. We expect the revenue to continue to grow as our customers update their requirements, processes and procedures to include decontamination and disinfecting services into their regular routines.
SteraMist product-based revenues for the three months ended March 31, 2020 and 2019, were approximately $6,638,000 and $1,029,000, representing an increase of $5,609,000 or 545% when compared to the same prior year period. The growth is attributable to increased mobile equipment orders and solution orders from our existing customer base as well as our new customers. We expect solution orders to continue to grow as the new and existing customers adopt new processes and requirements for decontamination and disinfecting services. We cannot determine the frequency or quantities at this time, as the industry is rapidly evolving.
picked up another 3000 to add to my stockpile
looks like last chance to get cheapies....I hope
No debt is awesome
somebody knows something!!!!! maybe a national story on STERAMIST???
looks like float is only 82.19 million shares.....anyone have idea if accurate ??
Thanks
seems like the selling is done, and zero debt ....time to run to where it should be 2-3$ IMO
Among these clinical trials, the randomized phase III PRE-VENT study is evaluating pacritinib, an agent primarily explored for the treatment of myelofibrosis, as treatment of patients with severe COVID-19 is underway in both the United States and Europe. Ruxolitinib (Jakafi), another agent from the oncology space, is being investigated as treatment of cytokine storm associated with COVID-19 in the global phase III RUXCOVID clinical trial. The BTK inhibitor acalabrutinib (Calquence) is under investigation in the CALAVI study for the treatment of cytokine storm in patients who are severely ill with COIVD-19.
The toxicity of these agents and many others is under evaluation in clinical trials to determine their effectiveness against COVID-19. Data has already begun to be shared with the FDA from some clinical trials, such as leronlimab, which had data recently published in a pre-print manuscript online. The FDA intends to engage with pharmaceutical sponsors and other government agencies to facilitate patient access to these potential treatments as soon as favorable results are seen.
not sure if this has already been posted
from Yahoo finance conversation board
CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020
Download as PDFMay 13, 2020 6:00am EDT
CytoDyn Submits Requested Datasets to FDA for Biologics License Application
VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today confirmed on May 11, 2020, it submitted all remaining parts of the Company’s Biologics License Application (“BLA”) for leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients to the U.S. Food and Drug Administration (“FDA”). Pursuant to FDA guidelines, CytoDyn informed the FDA it had submitted a complete BLA for rolling review.
As a next step, the FDA will start reviewing the BLA for completeness and will make a filing decision. After the BLA submission is deemed completed, the FDA assigns a Prescription Drug User Fee Act (PDUFA) goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA, and the Company plans to request a priority review for the BLA. A priority review designation, if granted, means the FDA’s goal is to take action on the application within six months of receipt (compared with 10 months under standard review).
About Coronavirus Disease 2019
CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients to the FDA on April 27, 2020 and submitted the additional FDA requested clinical datasets on May 11, 2020. After the BLA submission is considered completed, the FDA will make a filing decision and set a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA, and the Company plans to request a priority review for the BLA. A priority review designation means the FDA’s goal is to take action on the marketing application within six months of receipt (compared with 10 months under standard review).
In the setting of cancer, research has shown t
Dr Yo should join Bruce Petterson on the CC's....really in depth info and if Leronlimab can help in all the RANTES issues we should see SP go to the moon !!!!